Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	518.51B -51.9%
Revenue (ttm)	244.02B +2.5%
Net Income	19.61B -7.4%
EPS	3,271.97 +6.3%
Shares Out	6.56M
PE Ratio	24.18
Forward PE	17.19
Dividend	1,200.00 (1.54%)
Ex-Dividend Date	Sep 29, 2025

Volume	125,613
Open	78,500
Previous Close	77,700
Day's Range	77,500 - 83,000
52-Week Range	76,200 - 179,800
Beta	0.41
Analysts	Hold
Price Target	124,750.00 (+57.71%)
Earnings Date	Aug 13, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 718
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.

Analyst Summary

According to 4 analysts, the average rating for 086900 stock is "Hold." The 12-month stock price target is ₩124,750, which is an increase of 57.71% from the latest price.

Price Target

₩124,750

(57.71% upside)

Analyst Consensus: Hold